<DOC>
	<DOCNO>NCT00401596</DOCNO>
	<brief_summary>This multicenter , open label , randomize , control , safety trial subject age 6-75 year diagnosis moderate severe , persistent asthma . A total 1899 subject randomize ( 2:1 ) either active treatment group control group . Upon successful completion screen period ( ~2 week ) , subject enter 24 week study .</brief_summary>
	<brief_title>A Study Evaluate Safety Xolair Moderate Severe Persistent Asthma Patients ( ALTO )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Documented physician diagnosis moderate severe , persistent asthma , define National Heart , Lung , Blood Institute ( NHLBI ) guideline FEV1 &lt; 80 % predict height , age , sex history FEV1 &lt; 80 % Between 6 75 year old time screening ( Visit 1 [ Week 2 ] ) Current treatment follow medication : Moderate dos inhale steroid preparation daily basis least 30 day prior screen ; and/or oral steroid stable dose daily basis least 30 day prior screen ; currently treat least one follow drug daily basis stable dose least 30 day prior screen : longacting βadrenergic ( salmeterol ) , leukotriene receptor antagonist ( LTRA ) , xanthine derivative , sodium cromoglycate Signed informed consent ( case minor , consent must give child 's parent legal guardian ) Serum IgE level ≥ 30 IU/mL ≤ 1300 IU/mL body weight ≥ 20 kg ≤ 150 kg fell within protocoldefined dose table range For female childbearing potential , opinion investigator , use effective method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study Willingness participate fully duration study Current active AEE define require initiation increase oral steroid dose treatment least double inhaled steroid dose Thrombocytopenia evidence platelet &lt; 100,000/uL Pregnancy lactation Previous randomization study Use experimental drug within 30 day prior study screen Known hypersensitivity ingredient Xolair , include excipients ( sucrose , histidine , polysorbate 20 ) Diagnosis aspirin nonsteroidal antiinflammatory druginduced asthma Active lung disease asthma ( e.g. , chronic bronchitis , emphysema , cystic fibrosis , chronic obstructive pulmonary disease ) History smoke within 2 year study screen visit history smoke ≥ 10 pack year Significant systemic disease ( e.g. , infection , hematologic , renal , hepatic , coronary heart disease cardiovascular disease , endocrinologic gastrointestinal disease ) within previous 3 month History neoplasia History noncompliance medical regimens Any systemic condition require regular administration immunoglobulin</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ALTO</keyword>
</DOC>